Certara (NASDAQ:CERT) Trading Down 5.7% – Here’s Why

Certara, Inc. (NASDAQ:CERT)’s stock price fell 5.7% during trading on Friday . The stock traded as low as $6.87 and last traded at $6.8660. Approximately 793,302 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 3,683,374 shares. The stock had previously closed at $7.28.

Analysts Set New Price Targets

CERT has been the subject of several analyst reports. BMO Capital Markets reduced their price objective on Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. Robert W. Baird lowered their target price on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 12th. Craig Hallum cut their target price on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research note on Tuesday, May 12th. KeyCorp cut their target price on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. Finally, Morgan Stanley reduced their price target on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Certara has a consensus rating of “Hold” and a consensus price target of $8.85.

Certara Stock Performance

The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -69.30 and a beta of 1.46. The company has a fifty day moving average price of $5.77 and a two-hundred day moving average price of $6.71.

Certara (NASDAQ:CERT) last released its earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The firm had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. During the same period in the previous year, the firm earned $0.14 earnings per share. Certara’s revenue was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities research analysts expect that Certara, Inc. will post 0.24 EPS for the current year.

Hedge Funds Weigh In On Certara

Several hedge funds have recently made changes to their positions in CERT. Wasatch Advisors LP raised its holdings in shares of Certara by 28.6% in the 3rd quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock worth $212,608,000 after purchasing an additional 3,865,455 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Certara by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock worth $48,806,000 after buying an additional 175,024 shares in the last quarter. Deerfield Management Company L.P. boosted its holdings in Certara by 71.7% during the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after buying an additional 2,813,438 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in Certara by 27.1% during the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock worth $63,889,000 after buying an additional 1,165,064 shares in the last quarter. Finally, State Street Corp grew its position in Certara by 2.2% in the fourth quarter. State Street Corp now owns 3,918,784 shares of the company’s stock worth $34,524,000 after buying an additional 83,698 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.